Cargando…
Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome
Autores principales: | Moin, Abu Saleh Md, Nandakumar, Manjula, Sathyapalan, Thozhukat, Atkin, Stephen L., Butler, Alexandra E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876982/ https://www.ncbi.nlm.nih.gov/pubmed/33573655 http://dx.doi.org/10.1186/s12967-021-02723-7 |
Ejemplares similares
-
COVID-19 biomarkers for severity mapped to polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2020) -
Correction to: COVID-19 biomarkers for severity mapped to polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021) -
Vitamin D association with coagulation factors in polycystic ovary syndrome is dependent upon body mass index
por: Moin, Abu Saleh Md, et al.
Publicado: (2021) -
The relationship of soluble neuropilin-1 to severe COVID-19 risk factors in polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021) -
Components of the Complement Cascade Differ in Polycystic Ovary Syndrome
por: Butler, Alexandra E., et al.
Publicado: (2022)